Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. They develop treatments that utilize drugs to stimulate patient’s own stem cells.
Drs. Steven Cramer, Michael Hill and David Brown conducted clinical trial of beta-human Chorionic Gonadotropin (b-hCG) and Erythropoietin (EPO) to study their safety and efficacy in the diagnosis of Acute Ischemic Stroke.
Acute Ischemic Stroke is a type of stroke caused by thrombosis or embolism and accounts for 85% of all strokes.
The results of the trial can be summarized as:
1) No adverse effects were observed in the patients administered with NTx(TM).
2) Each of the participants recovered at least 4 points on the National Institute of Health Stroke Scale (NIHSS).
3) The therapy had minimal hematological effects and is associated with significant clinical gains.
These results were announced at the International Stroke Conference held at San Diego, CA on 19th of February, 2009.